Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 111-116

  Di Pasqua, Anthony J ^a   Yuan, Hong ^b   Chung, Younjee ^a   Kim, Jin Ki ^c   Huckle, James E ^a   Li, Chenxi ^d   Sadgrove, Matthew ^a   Tran, Thanh Huyen ^e   Jay, Michael ^a   Lu, Xiuling ^e  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Hanyang University   (South Korea)

^d IL   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Drug delivery; Holmium; Mesoporous silica nanoparticle; Ovarian cancer; Radiotherapeutics

Indexed keywords

HOLMIUM; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUTRON RADIATION; NONHUMAN; NUCLEAR REACTOR; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TISSUE DISTRIBUTION; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; FEMALE; GAMMA RAYS; HOLMIUM; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYBUTYRATES; MICE; NANOPARTICLES; NEUTRONS; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; PENTANONES; POROSITY; RADIOISOTOPES; SILICON DIOXIDE;

EID: 84872050514     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.106609     Document Type: Article

References (22)

1. Intraperitoneal therapy for ovarian cancers. National Cancer Institute Web site. Available at: http://www.cancer.gov/clinicaltrials/conducting/ developments/ipchemodigest/Pagel. Accessed October 19, 2012.
2. Spencer TR, Marks RD, Fenn JO, Jenrette JM, Lutz MH. Intraperitoneal P-32 after negative second-look laparotomy in ovarian carcinoma. Cancer. 1989;63:2434-2437.
3. Phosphocol P 32 (chromic phosphate P 32 suspension). U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094958.htm. Published August 29, 2008. Accessed March 19, 2012.
4. Tian JH, Xu BX, Zhang JM, Dong BW, Liang P, Wang XD. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med. 1996;37:958-963.
5. Mumper RJ, Yun Ryo U, Jay MJ. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med. 1991;32:2139-2143.
6. Zielhuis SW, Nijsen JFW, Seppenwoolde JH, et al. Long-term toxicity of holmium loaded poly(L-lactic acid) microspheres in rats. Biomaterials. 2007;28:4591-4599.
7. Bult W, Seevinck PR, Krijger GC, et al. Microspheres with ultrahigh holmium content for radioablation of malignancies. Pharm Res. 2009;26:1371-1378.
8. Zielhuis SW, Seppenwoolde JH, Bakker CJG, et al. Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications. J Biomed Mater Res A. 2007;82:892-898.
9. Kim JK, Han KH, Lee JT, et al. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12:543-548.
10. Hamoudeh M, Fessi H, Salim H, Barbos D. Holmium-loaded PLLA nanoparticles for intratumoral radiotherapy via the TMT technique: preparation, characterization, and stability evaluation after neutron irradiation. Drug Dev Ind Pharm. 2008;34:796-806.
11. Bult W, Varkevisser R, Soulimani F, et al. Holmium nanoparticles: preparation and in vitro characterization of a new device for radioablation of solid malignancies. Pharm Res. 2010;27:2205-2212.
12. Di Pasqua AJ, Huckle JE, Kim JK, et al. Preparation of neutron-activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small. 2012;8:997-1000.
13. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl. 2007;46:7548-7558.
14. Zeng W, Qian XF, Zhang YB, Yin J, Zhu ZK. Organic modified mesoporous MCM-41 through solvothermal process as drug delivery system. Mater Res Bull. 2005;40:766-772.
15. 2+ anticancer drug carboplatin by mesoporous silica. Chem Biodivers. 2009;6:1343-1349.
16. Di Pasqua AJ, Sharma KK, Shi YL, et al. Cytotoxicity of mesoporous silica nanomaterials. J Inorg Biochem. 2008;102:1416-1423.
17. Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials. 2008;29:4045-4055.
18. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6:1794-1805.
19. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353-359.
20. 90Y-microspheres for hepatocellular carcinoma. J Nucl Med. 2001;42:1587-1589.
21. Tandon P, Malpani BL, Venkatesh M, Bhatt BC. Estimation of radiation dose at various depths for commonly used radionuclides in radiosynoviorthesis in a tissue equivalent material. Med Phys. 2006;33:2744-2750.
22. Johnson LS, Yanch JC. Absorbed dose profiles for radionuclides of frequent use in radiation synovectomy. Arthritis Rheum. 1991;34:1521-1530.